Oxford Biomedica (LON:OXB) Shares Cross Below 200 Day Moving Average – What’s Next?

Oxford Biomedica plc (LON:OXB) shares passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 663.97 and traded as low as GBX 630. Oxford Biomedica shares last traded at GBX 648, with a volume of 353,135 shares traded.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Stifel Nicolaus restated a “buy” rating and set a GBX 950 price target on shares of Oxford Biomedica in a research note on Wednesday, March 11th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Oxford Biomedica from GBX 735 to GBX 800 and gave the company a “buy” rating in a report on Friday, January 9th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of GBX 663.67.

Oxford Biomedica Stock Up 0.6%

The company has a market cap of £783.25 million, a P/E ratio of -17.89 and a beta of 1.04. The company has a debt-to-equity ratio of 322.11, a current ratio of 1.89 and a quick ratio of 1.67. The stock has a fifty day moving average price of GBX 761.05 and a two-hundred day moving average price of GBX 663.97.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.